915 related articles for article (PubMed ID: 26121196)
21. Inhibition of interleukin-12 and/or interleukin-23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?
Ergen EN; Yusuf N
Exp Dermatol; 2018 Jul; 27(7):737-747. PubMed ID: 29704872
[TBL] [Abstract][Full Text] [Related]
22. New and emerging therapies in psoriasis.
Leonardi CL; Gordon KB
Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S37-41. PubMed ID: 24979544
[TBL] [Abstract][Full Text] [Related]
23. Briakinumab.
Lima XT; Abuabara K; Kimball AB; Lima HC
Expert Opin Biol Ther; 2009 Aug; 9(8):1107-13. PubMed ID: 19569977
[TBL] [Abstract][Full Text] [Related]
24. IL-12/IL-23 inhibitors: the advantages and disadvantages of this novel approach for the treatment of psoriasis.
Bartlett BL; Moody MN; Tyring SK
Skin Therapy Lett; 2008; 13(8):1-4. PubMed ID: 19145382
[TBL] [Abstract][Full Text] [Related]
25. Cytokine-dependent modification of IL-12p70 and IL-23 balance in dendritic cells by ligand activation of Valpha24 invariant NKT cells.
Uemura Y; Liu TY; Narita Y; Suzuki M; Nakatsuka R; Araki T; Matsumoto M; Iwai LK; Hirosawa N; Matsuoka Y; Murakami M; Kimura T; Hase M; Kohno H; Sasaki Y; Ichihara Y; Ishihara O; Kikuchi H; Sakamoto Y; Jiao SC; Senju S; Sonoda Y
J Immunol; 2009 Jul; 183(1):201-8. PubMed ID: 19542431
[TBL] [Abstract][Full Text] [Related]
26. Ustekinumab (Stelara) for Crohn's disease.
Med Lett Drugs Ther; 2017 Jan; 59(1511):5-6. PubMed ID: 28026835
[No Abstract] [Full Text] [Related]
27. Interleukin 32, inflammation and cancer.
Hong JT; Son DJ; Lee CK; Yoon DY; Lee DH; Park MH
Pharmacol Ther; 2017 Jun; 174():127-137. PubMed ID: 28223235
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-12, interleukin-23, and psoriasis: current prospects.
Torti DC; Feldman SR
J Am Acad Dermatol; 2007 Dec; 57(6):1059-68. PubMed ID: 17706835
[TBL] [Abstract][Full Text] [Related]
29. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab.
Guenova E; Teske A; Fehrenbacher B; Hoerber S; Adamczyk A; Schaller M; Hoetzenecker W; Biedermann T
Arch Dermatol; 2011 Oct; 147(10):1203-5. PubMed ID: 21680759
[TBL] [Abstract][Full Text] [Related]
30. IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases.
Li H; Tsokos GC
Clin Rev Allergy Immunol; 2021 Feb; 60(1):31-45. PubMed ID: 33185790
[TBL] [Abstract][Full Text] [Related]
31. Specific targeting of interleukin-23p19 as effective treatment for psoriasis.
Levin AA; Gottlieb AB
J Am Acad Dermatol; 2014 Mar; 70(3):555-61. PubMed ID: 24373779
[TBL] [Abstract][Full Text] [Related]
32. Ustekinumab: moving the target from psoriasis to Crohn's disease.
Settesoldi A; Coppola M; Rogai F; Annese V
Expert Rev Gastroenterol Hepatol; 2014 Jan; 8(1):5-13. PubMed ID: 24410468
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis.
Mudigonda P; Mudigonda T; Feneran AN; Alamdari HS; Sandoval L; Feldman SR
Dermatol Online J; 2012 Oct; 18(10):1. PubMed ID: 23122008
[TBL] [Abstract][Full Text] [Related]
34. Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target?
Chiricozzi A; Saraceno R; Chimenti MS; Guttman-Yassky E; Krueger JG
Expert Opin Ther Targets; 2014 May; 18(5):513-25. PubMed ID: 24568095
[TBL] [Abstract][Full Text] [Related]
35. The IL-12 cytokine family in cardiovascular diseases.
van der Heijden T; Bot I; Kuiper J
Cytokine; 2019 Oct; 122():154188. PubMed ID: 29074035
[TBL] [Abstract][Full Text] [Related]
36. Swords into plowshares: IL-23 repurposes tumor immune surveillance.
Langowski JL; Kastelein RA; Oft M
Trends Immunol; 2007 May; 28(5):207-12. PubMed ID: 17395538
[TBL] [Abstract][Full Text] [Related]
37. Differential effects of anti-TNF-α and anti-IL-12/23 agents on human leukocyte-endothelial cell interactions.
Ríos-Navarro C; de Pablo C; Collado-Diaz V; Orden S; Blas-Garcia A; Martínez-Cuesta MÁ; Esplugues JV; Alvarez A
Eur J Pharmacol; 2015 Oct; 765():355-65. PubMed ID: 26344475
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-12 family members and type I interferons in Th17-mediated inflammatory disorders.
Goriely S; Cavoy R; Goldman M
Allergy; 2009 May; 64(5):702-9. PubMed ID: 19383026
[TBL] [Abstract][Full Text] [Related]
39. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
Kurzeja M; Rudnicka L; Olszewska M
Am J Clin Dermatol; 2011 Apr; 12(2):113-25. PubMed ID: 21348542
[TBL] [Abstract][Full Text] [Related]
40. Could anti IL12/23 therapy replace anti-TNF biologics?
Ionescu MA; Lipozencić J
Acta Dermatovenerol Croat; 2009; 17(3):166-9. PubMed ID: 19818214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
